IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Darrell H. Carney

Continuation Application of

Application No.: PCT/US02/01151

Filed: January 16, 2002

For: USE OF THROMBIN-DERIVED PEPTIDES FOR THE THERAPY OF CHRONIC DERMAL ULCERS

Date: 1-27-04

EXPRESS MAIL LABEL NO. EV214935159US

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This Information Disclosure Statement is submitted:

[ ] under 37 CFR 1.129(a), or
(First/Second submission after Final Rejection)

[X] under 37 CFR 1.97(b), or
(Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, including a CPA, or a Request for Continued Examination).

[ ] under 37 CFR 1.97(c) together with either:

[ ] a Statement under 37 CFR 1.97(e), as checked below, or

[ ] a $180.00 fee under 37 CFR 1.17(p), or
(After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)

[ ] under 37 CFR 1.97(d) together with:

[ ] a Statement under 37 CFR 1.97(e), as checked below, and

[ ] a $180.00 fee under 37 CFR 1.17(p), or
(Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)

[ ] under 37 CFR 1.97(i):
Applicant requests that the IDS and cited reference(s) be placed in the application filewrapper.
(Filed after payment of issue fee)

Statement Under 37 CFR 1.97(e)

[ ] Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or

[ ] No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Statement Under 37 CFR 1.704(d) (Patent Term Adjustment)
Applies to original applications (other than design) filed on or after May 29, 2000

[ ] Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.

[X] Enclosed herewith is form PTO-1449:

[X] Copies of the cited references (AL-AM, AR-AZ and AR2-AS2) are enclosed.

[X] Since this application was filed after June 30, 2003, copies of issued U.S. patents (AA and AB) and published U.S. applications are not required and are not being provided.

[ ] Copies of the cited references are enclosed except those entered in prior application, U.S. Application No. [ ], to which priority under 35 U.S.C. 120 is claimed. [The earlier application contains copies of the cited references.]

[X] The listed references (AA, AL, AR and AS) were cited in the enclosed International Search Report in a counterpart foreign application.

[ ] The "concise explanation" requirement (non-English references) for reference(s) [ ] under 37 CFR 1.98(a)(3) is satisfied by:

[ ] the explanation provided on the attached sheet.

[ ] the explanation provided in the Specification.

[ ] submission of the enclosed International Search Report.

[ ] submission of the enclosed English-language version of a foreign Search Report and/or foreign Office Action.

[ ] the enclosed English language abstract.

[ ] Applicant requests that the following non-published pending applications be considered:

Examiner's Initials

_____ U.S. Patent Application No. [ ], by [inventor(s)], filed [ ], Docket No.: [ ]

_____ U.S. Patent Application No. [ ], by [inventor(s)], filed [ ], Docket No.: [ ]

_____ U.S. Patent Application No. [ ], by [inventor(s)], filed [ ], Docket No.: [ ]

_____ _____

Examiner Date

[ ] A copy of each above-cited application, including the current claims, is enclosed.

[ ] A copy of each above-cited application, including the current claims, is enclosed, except those entered in prior application, U.S. Application No. [ ], to which priority under 35 U.S.C. 120 is claimed.

The Examiner is requested to return a copy of the above list of pending applications indicating which references were considered with the next office communication.

It is requested that the information disclosed herein be made of record in this application.

Method of payment:

[ ] A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply. A copy of this Statement is enclosed.

[ ] Please charge Deposit Account 08-0380 in the amount of $[ ]. A copy of this Statement is enclosed.

[X] Please charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By _____

Helen Lee
Registration No.: 39,270
Telephone: (978) 341-0036
Facsimile: (978) 341-0136

Concord, MA 01742-9133

Dated: January 27, 2004

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 3033.1008-008	CONTINUATION APPLICATION OF NO. PCT/US02/01151
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	FIRST NAMED INVENTOR Darrell H. Carney	FILING DATE
January 27, 2004	EXAMINER	CONFIRMATION NO. / GROUP
(Use several sheets if necessary)		

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
	AA	5,352,664	10-04-1994	Carney *et al.*
	AB	5,500,412	03-19-1996	Carney *et al.*
	AC			
	AD			
	AE			
	AF			
	AG			
	AH			
	AI			
	AJ			
	AK			
	AA2			
	AB2			
	AC2			
	AD2			
	AE2			
	AF2			
	AG2			
	AH2			
	AI2			
	AJ2			
	AK2			
	AA3			
	AB3			
	AC3			

EXAMINER	DATE CONSIDERED

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO.	CONTINUATION APPLICATION OF NO.
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	3033.1008-008	PCT/US02/01151
	FIRST NAMED INVENTOR: Darrell H. Carney	FILING DATE
January 27, 2004	EXAMINER	CONFIRMATION NO. / GROUP
(Use several sheets if necessary)		

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES	TRANSLATION NO
	AL	WO 01/49309 A2	07-12-2001	Pfizer Limited		
	AM	WO 88/03151	05-05-1988	Board of Regents, The University of Texas System		
	AN					
	AO					
	AP					
	AQ					
	AL2					
	AM2					
	AN2					
	AO2					
	AP2					
	AQ2					
	AL3					
	AM3					
	AN3					
	AO3					
	AP3					
	AQ3					
	AL4					
	AM4					
	AN4					
	AO4					
	AP4					
	AQ4					

EXAMINER	DATE CONSIDERED

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 3033.1008-008	CONTINUATION APPLICATION OF NO. PCT/US02/01151	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	FIRST NAMED INVENTOR Darrell H. Carney	FILING DATE	
January 27, 2004 (Use several sheets if necessary)	EXAMINER	CONFIRMATION NO.	GROUP

		OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*
	AR	Stiernberg, J., *et al.*, "Acceleration of full-thickness wound healing in normal rats by the synthetic thrombin peptide, TP508," *Wound Repair and Regeneration,* 8(3):204-215 (2000).
	AS	Norfleet, A.M., *et al.*, "Thrombin peptide, TP508, stimulates angiogenic responses in animal models of dermal wound healing, in chick chorioallantoic membranes, and in cultured human aortic and microvascular endothelial cells," *General Pharmacology*, 35:249-254 (2002).
	AT	Norfleet, A.M., *et al.*, "Thrombin peptide TP508 accelerates closure of dermal excisions in animal tissue with surgically induced ischemia," *Wound Repair and Regeneration*, 8(6):517-529 (2000).
	AU	Pernia, S.D., *et al.*, "A Synthetic Peptide Representing the Thrombin Receptor-Binding Domain Enhances Wound Closure *In Vivo*," *SAAS Bulletin: Biochem. & Biotech.*, 3:8-12 (1990).
	AV	Carney, Darrell H., "Postclotting Cellular Effects of Thrombin Mediated by Interaction with High-Affinity Thrombin Receptors," In *Thrombin Structure and Function*, Berliner, L.J. (ed.) (New York: Plenum Press), pp. 351-396 (1992).
	AW	Stiernberg, J., *et al.*, "The Role of Thrombin and Thrombin Receptor Activating Peptide (TRAP-508) in Initiation of Tissue Repair," *Thrombosis and Haemostasis*, 70(1)158-162 (1993).
	AX	Carney, D.H., *et al.*, "Enhancement of Incisional Wound Healing and Neovascularization in Normal Rats by Thrombin and Synthetic Thrombin Receptor-activating Peptides," *J. Clin. Invest.*, 89:1469-1477 (1992).
	AY	Carney, D.H., *et al.*, "Role of High-Affinity Thrombin Receptors in Postclotting Cellular Effects of Thrombin," *Seminars in Thrombosis and Hemostasis*, 18(1):91-102 (1992).
	AZ	Glenn, K.C., *et al.*, "Synthetic Peptides Bind to High-Affinity Thrombin Receptors and Modulate Thrombin Mitogenesis," *Peptide Research*, 1(2):65-73 (1988).
	AR2	Sower, L.E., *et al.*, "Thrombin Peptide, TP508, Induces Differential Gene Expression in Fibroblasts through a Nonproteolytic Activation Pathway," *Experimental Cell Research*, 247:422-431 (1999).
	AS2	Steed, D.L., *et al.*, "Promotion and Acceleration of Diabetic Ulcer Healing by Arginine-Glycine-Aspartic Acid (RGD) Peptide Matrix," *Diabetes Care*, 18(1):39-46 (1995).

EXAMINER	DATE CONSIDERED